The evolution of 99mTc-NGA as a clinically useful receptor-binding radiopharmaceutical

Nuclear Medicine and Biology

Volumn 28, Issue 5, 2001, Pages 499-503

  Stadalnik, Robert C ^a,b   Vera, David R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSYLNEOGLYCOALBUMIN TC 99M; LECTIN; LIVER BINDING PROTEIN; RADIOPHARMACEUTICAL AGENT; SERUM GALACTOSYLALBUMIN TC 99M; UNCLASSIFIED DRUG;

ARTICLE; BILIARY CIRRHOSIS; BLOOD SAMPLING; CELL FUNCTION; CHRONIC HEPATITIS; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG SOLUBILITY; DRUG SPECIFICITY; HUMAN; IMAGING; ISOTOPE LABELING; LIVER BLOOD FLOW; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; NODULAR HYPERPLASIA; PROTEIN ANALYSIS; RECEPTOR AFFINITY;

ALBUMINS; ANIMALS; HUMANS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 0034976203     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00219-0     Document Type: Article

References (56)

1. Hepatic recognition and catabolism of serum glycoproteins
2. A quantitative model of technetium-99m-DTPA-galactosyl-HSA for the assessment of hepatic blood flow and hepatic binding receptor
3. Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: A multicenter study
4. A new liver function test using the asiologlycoprotein-receptor system on the liver cell membrane III. Evaluation for usefulness by liver function test using the Tc-99m-neoglycoprotein
5. 99Tc-DTPA-galactosyl-human serum albumin dynamic SPECT
6. Living-related auxiliary partial orthotopic liver transplantation for primary sclerosing cholangitis-subsequent removal of the native liver
7. Utility of Tc-99m GSA SPECT imaging in estimation of functional volume of liver segments in health and liver diseases
8. A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane. II. Quantitative evaluation of labeled neoglycoprotein clearance
9. Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease
10. Quantatitive evaluation of the hepatic functional reserve using Technetium-99m DTPA-galactosyl human serum albumin before and after transjugular intrahepatic portosystemic shunt
11. 99Tc-GSA hepatic scintigraphy with liver biopsies in patients with chronic active hepatitis type C
12. Liver allograft functional reserve estimated by total asialoglycoprotein receptor amount using Tc-GSA liver scintigraphy
13. Recovery of hepatic asialoglycoprotein receptors after major hepatic resection
14. A complementary radiopharmaceutical and model for quantitating hepatic binding protein receptors
15. 99mTc]-Neogalactoalbumin: A general model for some bifunctional carbohydrates
16. A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane. I. Evaluation of liver imaging using the Tc-99m-neoglycoprotein
17. 99mTc]galactosyl-neoglycoalbumin is sensitive to receptor quantity
18. Validation of in vivo receptor measurements via in vitro radioassay: Technetium-99m-galactosyl-neoglycoalbumin as a prototype model
19. Receptor index via hepatic asialoglycoprotein receptor imaging: Correlation with chronic hepatocellular damage
20. Quantitative assessment of hepatocellular function via in vivo radioreceptor imaging: Technetium-99m-galactosyl human serum albumin (Tc-GSA)
21. Distinction between hepatic focal nodular hyperplasia and malignant liver lesions using technetium-99m-galactosyl-neoglycoalbumin
22. Use of technetium 99m diethylenetriamine-pentaacetic acid-galactosyl-human serum albumin liver scintigraphy in the evaluation of preoperative and postoperative hepatic functional reserve for hepatectomy
23. Tc-99m galactosyl-neoglycoalbumin hepatic scintigraphy in fulminant hepatic failure
24. Liver scintigraphy is useful for selecting candidates for preoperative transarterial chemoembolization among patients with hepatocellular carcinoma and chronic liver disease
25. Perioperative hepatic functional risk assessed with technetium-99m diethylenetriamine pentaacetic acid-galactosyl human serum albumin liver scinitigraphy in patients undergoing pancreaticoduodenectomy complicated by obstructive jaundice
26. Evaluation of hepatocullar function via receptor-mediated uptake of a technetium-99m-labeled asialoglycoprotein analogue
27. Asialoglycoprotein receptor scintigraphy in evaluation of auxiliary partial orthotopic liver transplantation
28. 99mTc-galactosyl-human serum albumin for prognosis of cirrhosis of liver
29. Evaluation of fulminant hepatic failure by scintigraphy with technetium-99m GSA
30. 99mtechnetium galactosyl human serum albumin for staging of primary biliary cirrhosis and assessment of prognosis
31. Clinical experience with Tc-99m-galactosyl-neoglycoalbumin (Tc-NGA): A hepatic receptor-binding radiopharmaceutical
32. Technetium-99m-NGA functional hepatic imaging: Preliminary clinical experience
33. Receptor-binding radiopharmaceuticals: Experimental and clinical aspects
34. In vivo functional imaging using receptor-binding radiopharmaceuticals: Technetium-99m-galactosyl-neogly-coalbumin as a model
35. TIPS reduces hepatic asialoglycoprotein receptor concentration in healthy pigs
36. Hepatic binding protein: The galactose-specific receptor of mammalian hepatocytes
37. 99mTc-GSA SPECT and their usefulness in prognostic estimation after hepatectomy
38. 99mTc-GSA, a new agent for functional imaging of the liver
39. 99mTc-GSA, a new agent for functional imaging of the liver
40. 99mTc-GSA, a new agent for functional imaging of the liver
41. Use of Tc-99m DTPA galactosyl human serum albumin to predict postoperative residual liver functional
42. Radioligands that bind to cell-specific receptors: Hepatic binding protein ligands for hepatic scintigraphy
43. [Tc-99m]-galactosyl-neoglycoalbumin: In vivo characterization of receptor-mediated binding to hepatocytes
44. [Tc-99m]-galactosyl-neoglycoalbumin: In vitro characterization of receptor-mediated binding
45. Identifiability analysis of an in vivo receptor binding radiopharmacokinetic system
46. [Tc-99m]-galactosyl-neoglycoalbumin: Preparation and preclinical studies
47. Kinetic sensitivity of a receptor-binding radiopharmaceutical. Technetium-99m galactosyl-neoglycoalbumin
48. Measurement of receptor quantity and forward binding rate constant via radiopharmacokinetic modeling of [Tc-99m]-galactosyl-neoglycoalbumin
49. Local identifiability of a receptor-binding radiopharmacokinetic system having measured parameters of known uncertainty
50. Diagnostic performance of a receptor-binding radiopharmacokinetic model
51. 99mTc-neogalacto-albumin (NGA)-binding to human hepatic binding protein (HBP) in vitro
52. 99mTc-galactosyl-neoglycoalbumin
53. 99mTc-galactosyl-neoglycoalbumin
54. Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer
55. Tc-NGA imaging in liver transplantation: Preclinical studies
56. TcNGA imaging in liver transplantation: Preliminary clinical experience